New York, NY – October 24, 2018 – Sichenzia Ross Ference LLP, announced today that it represented Wize Pharma, Inc. (OTCQB: “WIZP”), a clinical stage Israel based U.S. public company focused on the treatment of ophthalmic disorders company, in a private placement with institutional and accredited investors of 3,100,000 shares of common stock at $1.00 per share and 1,350 shares of newly created Series A preferred stock which is convertible at $1.00 per share.
The investors also received 100% 5 year Series A and 100% 6 month Series B warrants exercisable at $1.00 per share and $1.10 per share respectively. Wize received gross proceeds of $4.45 million.
The Sichenzia Ross Ference LLP team was led by Partner Gregory Sichenzia and Counsel Jeff Cahlon.
- Sichenzia Ross Ference Carmel LLP Represents Brera Holdings PLC in $300 Million Crypto Treasury Private Placement - September 19, 2025
- Sichenzia Ross Ference Carmel LLP Represents Valkyrie X Investment Manager in $7.4 Million Series Investing in American Bitcoin Corp. - September 17, 2025
- Sichenzia Ross Ference Carmel LLP Represents Dominari IM and Dominari Securities in $20.1 Million Series Investing in American Bitcoin Corp. - September 17, 2025
